Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Angiotensins. --- Angiotensins --- Receptors.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Background Hypertension increases the risk of developing cardiovascular diseases, in particular myocardial infarction and stroke. Several types of drugs lower blood pressure and angiotensin receptor blockers (ARB) constitute one drug class. These drugs are also found in combination with thiazide diuretics. This report aimed to compare the different drugs within the ARB class with regard to efficacy and safety in patients with hypertension, heart failure and diabetic nephropathy. Method The report is an overview of systematic reviews. We have examined the effect of ARB on clinical endpoints like death, cardiovascular events (myocardial infarct, stoke) and end-stage renal disease. We performed systematic searches in Cochrane Library, Centre for Reviews and Dissemination databases, Medline (Ovid) and Embase (Ovid). Results We did not identify systematic reviews where drugs within the ARB class were directly compared. Neither did we find systematic reviews in which the combination drugs were compared. This applied to all clinical endpoints and all patient populations examined in this report. Studies that compared the different ARBs with other active drug treatments or with placebo, with use of hard endpoints (death, cardiovascular events, end stage renal failure), are present but few. For most comparisons with other active treatments significant differences with regard to efficacy have not been reported. Thus these studies could not be used as a basis for trying to undertake an indirect comparison between the different drugs within the ARB class. ARBs appeared to be well tolerated. The adverse events related to the ARBs varied between studies, and there were not sufficient data to determine whether differences existed between the different ARBs concerning specific adverse drug reactions. Conclusion It has not been documented that one or several drugs within the class of ARB are more efficacious or safer than the others in patients with hypertension, heart failure or diabetic nephropathy.

Angiotensins. --- Angiotensins --- Receptors.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Angiotensins. --- Angiotensins --- Receptors.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Angiotensins. --- Angiotensins --- Receptors.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Angiotensin: From the Kidney to Coronavirus, a new volume in the Molecular Mediators in Health and Disease series, presents the communication role of the hormone in both health and disease states. Beyond the most common conditions, the book also explores the role of Angiotensin in infectious diseases, like COVID-19. Sections provide background to its discovery and role in homeostasis, focus on molecular biology aspects, including genetics and measurements of its associated proteins, describe the specific actions of angiotensin in normal physiology with different organ systems, survey different classes of drugs that act on the Renin-angiotensin-aldosterone system, cover non-angiotensin II peptides, and more. The final part of the book is dedicated to angiotensin's role in disease states, making this the ideal reference for researchers in life sciences interested in understanding the physiological role of Angiotensin in a complete fashion. Research physicians will also benefit from the book's complete coverage of organ systems and diseases where Angiotensin plays a key role.

Angiotensins. --- Angiotensin --- Neuropeptides --- Oligopeptides --- Peptide hormones --- Angiotensins